Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
NULISA™ DBS 萃取試劑盒可從主流的第三方遙距採集樣本裝置收集的乾燥血點與乾燥血漿微量樣本中萃取蛋白質 此工作流程將 NULISA 的應用範圍擴展至縱向研究、去中心化研究，以及大規模族群研究 加州佛利蒙, June 04, 2026 (GLOBE NEWSWIRE) -- 致力於實現疾病最早期偵測的精準蛋白質體學頂尖機構 Alamar Biosciences, Inc....
-
NULISA™ DBS提取试剂盒可从主流第三方远程采样设备采集的干血斑、干血浆斑微量样本中提取蛋白质 该流程将NULISA技术推广至纵向研究、去中心化研究和大规模人群研究 加利福尼亚州弗里蒙特, June 04, 2026 (GLOBE NEWSWIRE) -- 致力于尽早发现疾病的精准蛋白质组学领先企业Alamar Biosciences, Inc. (Nasdaq: ALMR)...
-
NULISA™ DBS Extraction Kit recovers proteins from dried blood spot and dried plasma spot microsamples collected on leading third-party remote sampling devices Workflow extends NULISA into...
-
Fremont, CA, June 02, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today launched the...
-
FREMONT, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today reported...
-
FREMONT, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced...
-
FREMONT, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced...
-
FREMONT, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (“Alamar”), a leader in Precision Proteomics dedicated to advancing the early detection of disease, today announced the...
-
FREMONT, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (“Alamar”), a leader in precision proteomics dedicated to advancing the early detection of disease, today announced the...
-
New panel expands coverage for Alzheimer’s and Parkinson’s diseases including 15 new biomarkers developed with support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and 12 assays...